ReviewLife (Basel, Switzerland)2021
Sarcopenia and Frailty in Liver Cirrhosis.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The current state and development trends of frailty research in diabetic patients: a bibliometric analysis.Frontiers in medicine · 2025Pooled it
- Correlation between sarcopenia and cirrhosis: a meta-analysis.Frontiers in nutrition · 2023Pooled it
- The influence of prehabilitation in patients with liver cirrhosis before liver transplantation: a randomized clinical trial.European journal of physical and rehabilitation medicine · 2024Trial
- Co-Production of A Culturally Tailored Sarcopenia Screening Programme for Older Adults in Luton, UK: A Mixed-Methods Feasibility Study Protocol.Journal of frailty, sarcopenia and falls · 2026Article
- Identification of PTPRR gene associated with cirrhosis and sarcopenia based on bioinformatics and machine learning.European journal of clinical nutrition · 2026Article
- Gut Dysbiosis, Malnutrition and Sarcopenia in Liver Cirrhosis: A Narrative Review.Diseases (Basel, Switzerland) · 2026Review
- The Relationship Between FIB-4 Score and Dynapenia in Older Adults.Diagnostics (Basel, Switzerland) · 2025Article
- Bioelectrical impedance analysis-derived phase angle predicts osteosarcopenia and mortality in patients with chronic liver disease.Scientific reports · 2025Article
- Sarcopenia and frailty: An in-depth analysis of the pathophysiology and effect on liver transplant candidates.World journal of hepatology · 2025Review
- Impact of frailty and prevalent fractures on the long-term prognosis of patients with cirrhosis: a retrospective study.Scientific reports · 2025Article
- Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management.World journal of gastroenterology · 2023Review
- Review
- Hemoglobin and Endotoxin Levels Predict Sarcopenia Occurrence in Patients with Alcoholic Cirrhosis.Diagnostics (Basel, Switzerland) · 2023Article
- Review
- Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization.Journal of clinical medicine · 2022Article
- Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease.BMJ open gastroenterology · 2022Article
- Laboratory Profile of COVID-19 Patients with Hepatitis C-Related Liver Cirrhosis.Journal of clinical medicine · 2022Article
- Prediction of Patient Survival with Psoas Muscle Density Following Transjugular Intrahepatic Portosystemic Shunts: A Retrospective Cohort Study.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Influencing Factors and Molecular Pathogenesis of Sarcopenia and Osteosarcopenia in Chronic Liver Disease.Life (Basel, Switzerland) · 2021Review
- Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia.Nutrients · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscle is the largest organ in the body, and skeletal muscle atrophy results from a shift in the balance of protein synthesis and degradation toward protein breakdown. Primary sarcopenia is defined as a loss of skeletal muscle mass and strength or physical function due to aging, and secondary sarcopenia is defined as a loss of skeletal muscle mass and strength or physical function due to underlying diseases. Liver cirrhosis (LC) is one of the representative diseases which can be complicated with secondary sarcopenia. Muscle mass loss becomes more pronounced with worsening liver reserve in LC patients. While frailty encompasses a state of increased vulnerability to environmental factors, there is also the reversibility of returning to a healthy state with appropriate intervention. Several assessment criteria for sarcopenia and frailty were proposed in recent years. In 2016, the Japan Society of Hepatology created assessment criteria for sarcopenia in liver disease. In Japan, health checkups for frailty in the elderly aged 75 years or more started in April 2020. Both sarcopenia and frailty can be adverse predictors for cirrhotic patients. In this review article, we will summarize the current knowledge of sarcopenia and frailty in LC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.